Patents by Inventor Virginia Ammendola
Virginia Ammendola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240382583Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.Type: ApplicationFiled: March 19, 2024Publication date: November 21, 2024Applicant: GLAXOSMITHKLINE BIOLOICALS SAInventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI
-
Patent number: 11957749Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.Type: GrantFiled: December 14, 2018Date of Patent: April 16, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Virginia Ammendola, Babak Bayat, Clarisse Lorin, Ventzislav Bojidarov Vassilev, Alessandra Vitelli
-
Patent number: 11913013Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: GrantFiled: July 30, 2021Date of Patent: February 27, 2024Assignee: SABIN VACCINE INSTITUTEInventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 11795478Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: GrantFiled: May 11, 2022Date of Patent: October 24, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
-
Patent number: 11702674Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: GrantFiled: June 11, 2019Date of Patent: July 18, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
-
Publication number: 20230158134Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.Type: ApplicationFiled: December 5, 2022Publication date: May 25, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI, Benjamin WIZEL
-
Publication number: 20220275397Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: ApplicationFiled: May 11, 2022Publication date: September 1, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefania CAPONE, Stefano COLLOCA, Antonella FOLGORI, Rossella MERONE
-
Patent number: 11414679Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: GrantFiled: December 7, 2017Date of Patent: August 16, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone
-
Publication number: 20220220157Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: January 25, 2022Publication date: July 14, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefano COLLOCA, Riccardo CORTESE, Fabiana GRAZIOLI, Alfredo NICOSIA, Alessandra VITELLI
-
Publication number: 20220204566Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: ApplicationFiled: December 30, 2021Publication date: June 30, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano COLLOCA, Virginia AMMENDOLA, Fabiana GRAZIOLI, Alessandra Franz VITELLI, Alfredo NICOSIA, Riccardo CORTESE
-
Publication number: 20220112245Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.Type: ApplicationFiled: December 8, 2017Publication date: April 14, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI, Benjamin WIZEL
-
Patent number: 11268108Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.Type: GrantFiled: October 16, 2018Date of Patent: March 8, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefano Colloca, Alessandra Vitelli
-
Publication number: 20220064669Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).Type: ApplicationFiled: July 30, 2021Publication date: March 3, 2022Inventors: Nancy J. Sullivan, Gary J. Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
-
Patent number: 11254710Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: GrantFiled: June 10, 2016Date of Patent: February 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Virginia Ammendola, Fabiana Grazioli, Alessandra Franz Vitelli, Alfredo Nicosia, Riccardo Cortese
-
Patent number: 11254711Abstract: There is provided inter alia an isolated polynucleotide, wherein the polynucleotide encodes a polypeptide selected from the group consisting of: (a) a polypeptide having the amino acid sequence according to SEQ ID NO: 1, (b) a functional derivative of a polypeptide having the amino acid sequence according to SEQ ID NO: 1, wherein the functional derivative has an amino acid sequence which is at least 80% identical over its entire length to the amino acid sequence of SEQ ID NO: 1, and (c) a polypeptide having the amino acid sequence according to SEQ ID NO: 3.Type: GrantFiled: June 10, 2016Date of Patent: February 22, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefano Colloca, Riccardo Cortese, Fabiana Grazioli, Alfredo Nicosia, Alessandra Vitelli
-
Patent number: 11214599Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.Type: GrantFiled: December 11, 2019Date of Patent: January 4, 2022Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Stefano Colloca, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Maria Ambrosio
-
Publication number: 20210269486Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.Type: ApplicationFiled: December 8, 2017Publication date: September 2, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Virginia AMMENDOLA, Stefaano COLLOCA, Alessandra VITELLI, Benjamin Wizel
-
Publication number: 20210246468Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: ApplicationFiled: June 11, 2019Publication date: August 12, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefania CAPONE, Stefano COLLOCA, Antonella FOLGORI, Rosella MERONE
-
Publication number: 20210189421Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.Type: ApplicationFiled: October 16, 2018Publication date: June 24, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Stefano COLLOCA, Alessandra VITELLI
-
Publication number: 20210154290Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.Type: ApplicationFiled: December 14, 2018Publication date: May 27, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia AMMENDOLA, Babak BAYAT, Clarisse LORIN, Ventzislav Bojidarov VASSILEV, Alessandra VITELLI